Singapore – March 15, 2016 – Vishuo Biomedical has signed a Memorandum of Understanding (MOU) with the National Supercomputing Centre (NSCC).
Under the MOU, Vishuo Biomedical and the NSCC intend to test the capability, stability and security of Vishuo’s Individual Customised Medicine Database (iCMDB) on Supercomputing IT infrastructure over a period of 3 years.
The MOU was signed between Mr. Guo Dongliang, Managing Director, Vishuo Biomedical and Associate Professor Tan Tin Wee, Director, National Supercomputing Centre. This took place on the sidelines of the 2016 Supercomputing Frontiers Conference.
The newly launched National Supercomputing Centre will provide state-of-the-art national facility with computing, data and resources to enable users to solve science and technological problems, and stimulate industry to use computing for problem solving, testing designs and advancing technologies. Facility is linked by high bandwidth networks to connect these resources and provide high speed access to users anywhere and everyone. As part of the Smart Nation Strategy in Singapore, the NSCC will help improve key industries including healthcare, manufacturing, transportation and others.
Being one of the first batch of companies who were invited to collaborate with NSCC, Vishuo Biomedical is the only one who provides integrated precision medicine solution for prognosis, diagnosis and treatment. Through this collaboration, we intend to explore better computing power and storage solution for our customers around the world. Other companies who signed the MOU include Keppel Data Centres, National University of Singapore, Raffles Hospital and etc.
About Vishuo Biomedical
Vishuo Biomedical Pte Ltd is a Singapore based healthcare technology company formed in 2011, dedicated to provide precision medicine for prognosis, diagnosis and treatment. Our vision is to organize and analyse world’s pathological big data and optimize treatment for clinicians and patients.
Our core product, iCMDBTM, advances customized analysis of diseases on molecular level tailored to clinicians in conducting personalized treatment based on patients’ genetic and pathology profiles. To date, there are more than 200 diseases, 750 treatments and 1200 biomarkers in the datasets, all datasets are constantly reviewed and validated by experts in life sciences and medical consultants. To ensure good management of patient data, we protect and encrypt confidential personal information by deploying on-site server installed with iCMDBTM platform and customize analysis pipelines to generate automated data quality reports and clinical annotation reports for supporting clinical decision-making.